The CSL Ltd (ASX: CSL) share price is a long way from where it used to be.
At $139.44, it is sitting closer to its 52-week lows than anything resembling its former peak. That peak was $342.75 back in February 2020, when CSL was widely seen as one of the ASX's most dependable growth stories.
I think that contrast is striking. The same business that once traded at a premium for its consistency is now being priced far more cautiously.
Image source: Getty Images
A shift in how the market sees CSL and its shares
For a long time, CSL benefited from a very clear narrative.
It was a high-quality global biotechnology company with reliable growth, strong margins, and a pipeline that supported long-term expansion. Investors were comfortable paying up for that combination because the company delivered on it consistently.
That narrative has become less certain.
Over the past couple of years, CSL has been working through a period where growth has been less predictable and more dependent on a range of moving parts across its business.
In its latest update, the company reported a decline in revenue and underlying earnings for the half, while reported profit was heavily impacted by restructuring costs and impairments.
That alone does not tell the full story.
From consistency to complexity
One way I think about the current situation is that CSL has moved from being a relatively straightforward growth story to a more complex one.
Different parts of the business are moving at different speeds.
Some products are facing changes in pricing or policy settings in key markets. Others are dealing with increased competition or weren't granted approval as expected. At the same time, the company is investing in new therapies, expanding manufacturing, and reshaping its business.
All of that adds layers. For investors, more moving parts often leads to more uncertainty, and that can influence how a company is valued, even if the long-term opportunity remains intact.
Still building for the next phase
What I find interesting is that CSL is still actively positioning itself for future growth.
The transformation program underway is designed to improve efficiency and simplify operations, while ongoing investment in research and development continues to build out the pipeline.
There are also new products coming through that could contribute more meaningfully over time, alongside existing therapies that remain central to the business.
To me, that suggests the company is focused on its next phase rather than standing still.
So, what could $10,000 become?
If CSL shares were to return to their record high of $342.75, investors would be laughing all the way to the bank.
That would represent an increase of roughly 145% from the current price of $139.44.
Based on that, a $10,000 investment today would grow to approximately $24,500 if the shares were to revisit that level.
But that is a big if.
Foolish takeaway
CSL is in a different phase to the one investors became used to over the past decade. The business now has more moving parts, more investment underway, and a broader set of factors influencing performance.
That has led to a reset in expectations and a lower share price.
At the same time, the company continues to invest in its future and build out its next wave of growth. If that plays out as hoped, the gap between the current share price and its previous high could narrow. But it is not guaranteed and could take some time to happen.
